FSD Pharma Announces Positive ISA Report for “Steady Stomach” CBD Combination
FSD Pharma Inc. (“FSD Pharma“) (CSE: HUGE) (OTCQB: FSDDF) (FRA: 0K9) announced today that its strategic R&D partner, SciCann Therapeutics Inc. (“SciCann“) received a positive International Search Authority (ISA) report from the Patent Cooperation Treaty (PCT) for its SCN-001 cannabidiol (CBD) combination therapy, the basis of its “Steady Stomach” product.